Bazedoxifene/Conjugated Estrogen
Phase 3Completed 0 watching 0 views this week๐ Rising
76
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 24
Phase 35
ApprovedIndication / Disease
Vasomotor Symptoms Associated With Menopause
Conditions
Vasomotor Symptoms Associated With Menopause
Trial Timeline
Oct 1, 2005 โ Feb 1, 2007
NCT ID
NCT00234819About Bazedoxifene/Conjugated Estrogen
Bazedoxifene/Conjugated Estrogen is a phase 3 stage product being developed by Pfizer for Vasomotor Symptoms Associated With Menopause. The current trial status is completed. This product is registered under clinical trial identifier NCT00234819. Target conditions include Vasomotor Symptoms Associated With Menopause.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00238732 | Phase 3 | Completed |
| NCT00234819 | Phase 3 | Completed |
Competing Products
20 competing products in Vasomotor Symptoms Associated With Menopause